SCHEMBL6092491

SCHEMBL6092491

O=C(Nc1cc(O)ccc1C(=O)O)c1cccc(O)c1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKR1C4 P17516 4/20 0.68
AKR1C3 P42330 4/20 0.68
AKR1C2 P52895 4/20 0.68
AKR1C1 Q04828 4/20 0.68
MEN1 O00255 7/20 0.67
KMT2A Q03164 7/20 0.67
PKM P14618 2/20 0.67
MAPT P10636 4/20 0.63
TDP1 Q9NUW8 4/20 0.63
ALDH1A1 P00352 3/20 0.63
ABL1 P00519 1/20 0.63
TSHR P16473 1/20 0.63
RIN1 Q13671 1/20 0.63
GRIK1 P39086 2/20 0.57
GFER P55789 2/20 0.56
LMNA P02545 1/20 0.54
RAB9A P51151 1/20 0.54
CA12 O43570 1/20 0.53
CA1 P00915 1/20 0.53
CA2 P00918 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL637477 0.90 KMT2A (0.70) AKR1C4AKR1C3AKR1C2AKR1C1MEN1
SCHEMBL6091063 0.89 MEN1 (0.84) AKR1C4AKR1C3AKR1C2AKR1C1MEN1
SCHEMBL6091702 0.89 MEN1 (0.78) AKR1C4AKR1C3AKR1C2AKR1C1MEN1
SCHEMBL2272270 0.87 SUCNR1 (0.67) AKR1C4AKR1C3AKR1C2AKR1C1MEN1
SCHEMBL4669087 0.85 MEN1 (0.65) AKR1C4AKR1C3AKR1C2AKR1C1MEN1
SCHEMBL2275060 0.84 AKR1C4 (0.59) AKR1C4AKR1C3AKR1C2AKR1C1MEN1
SCHEMBL9973845 0.83 TOP1 (0.59) AKR1C4AKR1C3AKR1C2AKR1C1MEN1
SCHEMBL2271193 0.82 ACLY (0.64) AKR1C4AKR1C3AKR1C2AKR1C1MEN1
SCHEMBL9973843 0.81 TOP1 (0.58) MEN1KMT2APKMMAPTTDP1
SCHEMBL6350875 0.81 AKR1C2 (1.00) AKR1C4AKR1C3AKR1C2AKR1C1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230129036-A1 AVENANTHRAMIDE COMPOSITIONS WITH IMPROVED SOLUBILITY COMPRISING 4-HYDROXYPHENONE SYMRISE AG (DE) 2023-04-27 US disclosed
US-20230129036-A1 AVENANTHRAMIDE COMPOSITIONS WITH IMPROVED SOLUBILITY COMPRISING 4-HYDROXYPHENONE SYMRISE AG (DE) 2023-04-27 US disclosed
US-20230131993-A1 COMPOSITION COMPRISING AN AVENANTHRAMIDE OR AN ANALOGUE THEREOF WITH IMPROVED STABILITY SYMRISE AG (DE) 2023-04-27 US disclosed
US-20230131993-A1 COMPOSITION COMPRISING AN AVENANTHRAMIDE OR AN ANALOGUE THEREOF WITH IMPROVED STABILITY SYMRISE AG (DE) 2023-04-27 US disclosed
US-20230118467-A1 COSMETIC OR PHARMACEUTICAL USE OF AVENANTHRAMIDE L SYMRISE AG (DE) 2023-04-20 US disclosed
US-8911795-B2 Compositions comprising dihydroavenanthramide D and climbazole as cosmetic and pharmaceutical compositions for alleviating itching SYMRISE AG (DE) 2014-12-16 US disclosed
US-8911795-B2 Compositions comprising dihydroavenanthramide D and climbazole as cosmetic and pharmaceutical compositions for alleviating itching SYMRISE AG (DE) 2014-12-16 US disclosed
US-8409552-B2 Anthranillic acid amides and derivatives thereof as cosmetic and pharmaceutical active compounds SYMRISE AG (DE) 2013-04-02 US disclosed
US-8409552-B2 Anthranillic acid amides and derivatives thereof as cosmetic and pharmaceutical active compounds SYMRISE AG (DE) 2013-04-02 US disclosed
US-8409552-B2 Anthranillic acid amides and derivatives thereof as cosmetic and pharmaceutical active compounds SYMRISE AG (DE) 2013-04-02 US disclosed
US-8203016-B2 Anthranilic acid amides and derivatives thereof as cosmetic and pharmaceutical agents SYMRISE AG (DE) 2012-06-19 US disclosed
US-20090297468-A1 Mixtures Comprising Anthranilic Acid Amides and Cooling Agents as Cosmetic and Pharmaceutical Compositions for Alleviating Itching SYMRISE GMBH & CO. KG (DE) 2009-12-03 US disclosed
US-20090297468-A1 Mixtures Comprising Anthranilic Acid Amides and Cooling Agents as Cosmetic and Pharmaceutical Compositions for Alleviating Itching SYMRISE GMBH & CO. KG (DE) 2009-12-03 US disclosed
US-20090226537-A1 MIXTURES COMPRISING ANTHRANILIC ACID AMIDES AND ANTIDANDRUFF AGENTS AS COSMETIC AND PHARMACEUTICAL COMPOSITIONS FOR ALLEVIATING ITCHING SYMRISE GMBH & CO. KG (DE) 2009-09-10 US disclosed
US-20090226537-A1 MIXTURES COMPRISING ANTHRANILIC ACID AMIDES AND ANTIDANDRUFF AGENTS AS COSMETIC AND PHARMACEUTICAL COMPOSITIONS FOR ALLEVIATING ITCHING SYMRISE GMBH & CO. KG (DE) 2009-09-10 US disclosed
EP-1886662-A1 Anti-microbial compounds for treating bad breath Symrise GmbH & Co. KG (DE) 2008-02-13 EP disclosed
US-20080008660-A1 Antimicrobially active compounds for treating bad breath SYMRISE GMBH & CO. KG (DE) 2008-01-10 US disclosed
US-20080008660-A1 Antimicrobially active compounds for treating bad breath SYMRISE GMBH & CO. KG (DE) 2008-01-10 US disclosed
WO-2007062957-A1 MIXTURES COMPRISING ANTHRANILIC ACID AMIDES AND ANTIDANDRUFF AGENTS AS COSMETIC AND PHARMACEUTICAL COMPOSITIONS FOR ALLEVIATING ITCHING SYMRISE GMBH & CO. KG (DE) 2007-06-07 WO disclosed
US-20060089413-A1 Anthranilic acid amides and derivatives thereof as cosmetic and pharmaceutical agents SYMRISE GMBH & CO. KG (DE) 2006-04-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060089413-A1 Anthranilic acid amides and derivatives thereof as cosmetic and pharmaceutical agents HRH1, CMA1, HRH2 AKR1C4 1811/4885AKR1C3 1567/4885AKR1C2 1447/4885
US-20090297468-A1 Mixtures Comprising Anthranilic Acid Amides and Cooling Agents as Cosmetic and Pharmaceutical Compositions for Alleviating Itching H1-0, ASIC1, MCOLN1 AKR1C4 420/4885AKR1C3 194/4885AKR1C2 351/4885
US-20230129036-A1 AVENANTHRAMIDE COMPOSITIONS WITH IMPROVED SOLUBILITY COMPRISING 4-HYDROXYPHENONE HPD, CYP4A22, PAH AKR1C4 96/4885AKR1C3 177/4885AKR1C2 105/4885
US-20090226537-A1 MIXTURES COMPRISING ANTHRANILIC ACID AMIDES AND ANTIDANDRUFF AGENTS AS COSMETIC AND PHARMACEUTICAL COMPOSITIONS FOR ALLEVIATING ITCHING H1-0, ASIC1, NHERF1 AKR1C4 531/4885AKR1C3 268/4885AKR1C2 454/4885
US-20230131993-A1 COMPOSITION COMPRISING AN AVENANTHRAMIDE OR AN ANALOGUE THEREOF WITH IMPROVED STABILITY OAT, PIGS, HLA-A AKR1C4 1078/4885AKR1C3 1591/4885AKR1C2 946/4885
US-20080008660-A1 Antimicrobially active compounds for treating bad breath CAT, LPO, GPX1 AKR1C4 756/4885AKR1C3 729/4885AKR1C2 791/4885
US-20230118467-A1 COSMETIC OR PHARMACEUTICAL USE OF AVENANTHRAMIDE L TACR1, NPSR1, TACR2 AKR1C4 143/4885AKR1C3 108/4885AKR1C2 78/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.